GenFleet Therapeutics (Shanghai) Inc. completed an on-market repurchase of 319,000 H-shares on 18 September 2026, the company disclosed in a Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The shares were bought back at prices ranging from HK$24.80 to HK$26.44, resulting in a volume-weighted average cost of HK$25.45 and an aggregate consideration of HK$8.12 million. The transaction represents 0.091% of GenFleet’s outstanding H-shares prior to the repurchase.

Following the buyback, the company’s issued share capital (excluding treasury shares) fell to 350.76 million shares from 351.08 million, while treasury shares increased to 872,000. Total issued shares, including treasury stock, remain unchanged at 351.63 million.

The repurchase forms part of the mandate approved by shareholders on 11 May 2026, which authorises the company to buy back up to 37.04 million shares. Cumulative repurchases under this mandate now total 872,000 shares—0.235% of the share count on the mandate date.

In accordance with listing rules, GenFleet is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 October 2026.